Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)

Lignende værker

• Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study)
  af: Iwasaku, Masahiro, et al.
  Udgivet: (2019)
• Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study)
  af: Chihara, Yusuke, et al.
  Udgivet: (2019)
• Tumor Neovascularization and Developments in Therapeutics
  af: Katayama, Yuki, et al.
  Udgivet: (2019)
• Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment
  af: Uchino, Junji, et al.
  Udgivet: (2018)
• Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions
  af: Imabayashi, Tatsuya, et al.
  Udgivet: (2019)